Vericel Corporation (VCEL) Position Cut by KCG Holdings Inc.
KCG Holdings Inc. lowered its stake in shares of Vericel Corporation (NASDAQ:VCEL) by 30.6% during the first quarter, Holdings Channel reports. The fund owned 45,804 shares of the biotechnology company’s stock after selling 20,210 shares during the period. KCG Holdings Inc.’s holdings in Vericel Corporation were worth $128,000 as of its most recent SEC filing.
Separately, Renaissance Technologies LLC raised its position in Vericel Corporation by 0.5% in the fourth quarter. Renaissance Technologies LLC now owns 436,900 shares of the biotechnology company’s stock valued at $1,311,000 after buying an additional 2,200 shares during the last quarter. 31.99% of the stock is owned by hedge funds and other institutional investors.
Shares of Vericel Corporation (VCEL) traded down 1.47% on Thursday, reaching $3.35. The company’s stock had a trading volume of 58,745 shares. The stock’s market cap is $109.77 million. The company’s 50 day moving average is $3.25 and its 200-day moving average is $2.87. Vericel Corporation has a 1-year low of $2.00 and a 1-year high of $4.55.
Vericel Corporation (NASDAQ:VCEL) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.17. On average, equities analysts predict that Vericel Corporation will post ($0.63) earnings per share for the current fiscal year.
Several research firms recently weighed in on VCEL. Piper Jaffray Companies reissued a “buy” rating and set a $7.00 price target on shares of Vericel Corporation in a research report on Thursday. BTIG Research set a $6.00 price target on Vericel Corporation and gave the company a “buy” rating in a research report on Wednesday.
About Vericel Corporation
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corporation (NASDAQ:VCEL).
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.